KULR Technology Group Delivers Customized Battery Solution for U.S. Army, Enhancing Tactical Command Operations
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), an […]
AXIL Brands, Inc. Reports Third Quarter Fiscal Year 2024 Financial Results
LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) — AXIL Brands, Inc. (“AXIL,” “we,” “us,” “our,” or the “Company”) (NYSE American: […]
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage […]
Cellebrite to Report First-Quarter 2024 Financial Results on May 23, 2024
TYSONS CORNER, Va. and PETAH TIKVA, Israel, April 10, 2024 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in […]
AFC Gamma, Inc. Schedules First Quarter 2024 Earnings Conference Call for May 9, 2024
WEST PALM BEACH, Fla., April 10, 2024 (GLOBE NEWSWIRE) — AFC Gamma, Inc. (NASDAQ:AFCG) (“AFC Gamma”) today announced that it […]
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will […]
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating […]
Blue Foundry Bancorp Schedules First Quarter 2024 Earnings Conference Call
RUTHERFORD, N.J., April 10, 2024 (GLOBE NEWSWIRE) — Blue Foundry Bancorp (NASDAQ: BLFY) (the “Company”), the holding company for Blue […]
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year […]
Navient to announce first quarter 2024 results, host earnings webcast April 24
HERNDON, Va., April 10, 2024 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI), a leader in technology-enabled education finance and business processing […]
